×
About 49,305 results

ALLMedicine™ Psoriasis Center

Research & Reviews  13,187 results

Limited treatment options exist for brittle nail syndrome
https://www.mdedge.com/dermatology/article/262100/hair-nails/limited-treatment-options-exist-brittle-nail-syndrome
Doug Brunk

Mar 29th, 2023 - NEW ORLEANS – Limited treatment options exist for brittle nail syndrome, a heterogeneous abnormality characterized by increased nail plate fragility, with nails that split, flake, crumble, and become soft and lose elasticity. “The mainstay of trea.

Palbociclib blocks neutrophilic PI3K activity to alleviate psoriasiform dermatitis.
https://doi.org/10.1111/bph.16080
British Journal of Pharmacology; Chen PJ, Tseng HH et. al.

Mar 28th, 2023 - Neutrophilic inflammation is a critical pathogenic factor in psoriasis. The therapeutic applicability of palbociclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor clinically used to treat cancer, in the treatment of neutrophil-associated p...

Sodium in the Skin: A summary of the physiology and scoping review of disease associati...
https://doi.org/10.1093/ced/llad080
Clinical and Experimental Dermatology; Chattopadhyay A, Tully J et. al.

Mar 28th, 2023 - A large and growing body of research suggests that the skin plays an important role in regulating total body sodium, challenging traditional models of sodium homeostasis that focused exclusively on blood pressure and the kidney. In addition, skin ...

Bimekizumab maintenance of response through three years in patients with moderate to se...
https://doi.org/10.1093/bjd/ljad035
The British Journal of Dermatology; Strober B, Tada Y et. al.

Mar 28th, 2023 - Given the chronic nature of psoriasis and the loss of response that can be observed with therapies over time, it is important to understand the long-;term efficacy of new treatments. To evaluate maintenance of Week 16 responses with bimekizumab tr...

An update on therapeutic options for palmoplantar pustulosis: a narrative review and ex...
https://doi.org/10.1080/1744666X.2023.2185775
Expert Review of Clinical Immunology; Xu JM, Wang HM et. al.

Mar 28th, 2023 - Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease belonging to the localized form of pustular psoriasis. It is characterized by sterile pustule formation in palms and soles and a recurrent disease course. Although we have many t...

see more →

Guidelines  26 results

Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375973/
Psoriasis (Auckl); Gisondi P, Bellinato F et. al.

Nov 10th, 2022 - Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory arthritis associated with psoriasis, which may manifest with different domains such as dactylitis, enthesitis, synovitis and spondylitis. The estimated prevalence of PsA in patients...

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older/
Arcutis Biotherapeutics, Inc.

Jul 29th, 2022 - WESTLAKE VILLAGE, Calif., July 29, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced today that t...

Prevalence of comorbidities in atopic dermatitis and psoriasis in the French population
https://www.sciencedirect.com/science/article/abs/pii/S0151963820301915
Annales De Dermatologie Et De Vénéréologie; Richard MA, .

Mar 28th, 2021 - Atopic dermatitis (AD) and psoriasis (Pso) are highly prevalent chronic inflammatory skin diseases. They share similarities regarding severity and impact on quality of life but display differences regarding risk factors, comorbidities, and pathoge...

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specifi...
https://doi.org/10.1111/jdv.16926
Journal of the European Academy of Dermatology and Venere... Nast A, Smith C et. al.

Feb 7th, 2021 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clini...

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788316
Journal of the American Academy of Dermatology; Gelfand JM, Armstrong AW et. al.

Jan 11th, 2021 - To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical ca...

see more →

Drugs  1,166 results see all →

Clinicaltrials.gov  1,788 results

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
https://clinicaltrials.gov/ct2/show/NCT03556202

Mar 21st, 2023 - The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT04772079

Mar 16th, 2023 - The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in pediatric participants aged 4 to <18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to...

Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis
https://clinicaltrials.gov/ct2/show/NCT05499416

Mar 15th, 2023 - This study is being conducted to evaluate the effects of bimekizumab administered subcutaneously (SC) to patients with psoriasis vulgaris and who also have active PsA who have an inadequate skin response to anti-interleukin (IL)23 therapy. Approxi...

A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis
https://clinicaltrials.gov/ct2/show/NCT04439526

Mar 15th, 2023 - The purpose of this study is to investigate the effectiveness profile of guselkumab used in a real-life setting in participants with moderate facial and/or genital psoriasis. Effectiveness will be evaluated using the static Physicians Global Asses...

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
https://clinicaltrials.gov/ct2/show/NCT03451851

Mar 15th, 2023 - The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.

see more →

News  3,432 results

Limited treatment options exist for brittle nail syndrome
https://www.mdedge.com/dermatology/article/262100/hair-nails/limited-treatment-options-exist-brittle-nail-syndrome
Doug Brunk

Mar 29th, 2023 - NEW ORLEANS – Limited treatment options exist for brittle nail syndrome, a heterogeneous abnormality characterized by increased nail plate fragility, with nails that split, flake, crumble, and become soft and lose elasticity. “The mainstay of trea.

Expert shares her tips for diagnosing, treating onychomycosis
https://www.mdedge.com/dermatology/article/262000/hair-nails/expert-shares-her-tips-diagnosing-treating-onychomycosis
Doug Brunk

Mar 23rd, 2023 - NEW ORLEANS – Don’t treat suspected cases of onychomycosis before confirming the diagnosis with a laboratory test, Boni E. Elewski, MD, advises.

Ultrasound helps screen patients with moderate-to-severe psoriasis progressing to subclinical PsA
https://www.mdedge.com/psoriatic-arthritis-icymi/article/261986/psoriatic-arthritis/ultrasound-helps-screen-patients

Mar 23rd, 2023 - Key clinical point: In patients with moderate-to-severe psoriasis, the presence of synovio-enthesitis on ultrasound, particularly in lower limbs, indicated progression to subclinical psoriatic arthritis (PsA). Therefore, routine ultrasound screeni.

JAKi effective for PsA but higher doses may have increased toxicity
https://www.mdedge.com/psoriatic-arthritis-icymi/article/261984/psoriatic-arthritis/jaki-effective-psa-higher-doses-may

Mar 23rd, 2023 - Key clinical point: All Janus kinase inhibitors (JAKi) were more effective than placebo in patients with psoriatic arthritis (PsA), but led to a higher overall incidence of adverse events, particularly at higher doses. Major finding: JAKi vs place.

Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome: An Adverse Effect in a Patient With Atopic Dermatitis
https://www.mdedge.com/dermatology/article/261783/atopic-dermatitis/cyclosporine-induced-posterior-reversible
Clinton P. Dunn, MD, Charles L. Dunn, MD et. al.

Mar 14th, 2023 - To the Editor: Cyclosporine is an immunomodulatory medication that impacts T-lymphocyte function through calcineurin inhibition and suppression of IL-2 expression. Oral cyclosporine at low doses (1–3 mg/kg/d) is one of the more common systemic tre.

see more →

Patient Education  123 results see all →